Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1

Drug Metabolism and Disposition

Volumn 41, Issue 9, 2013, Pages 1671-1678

  Meyer, Arne ^a   Vuorinen, Anna ^b   Zielinska, Agnieszka E ^c   Strajhar, Petra ^a   Lavery, Gareth G ^c   Schuster, Daniela ^b   Odermatt, Alex ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; AMFEBUTAMONE; CARBONYL REDUCTASE; CORTISONE; DRUG; DRUG METABOLITE; ERYTHROHYDROBUPROPION; THREOHYDROBUPROPION; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL LYSATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; REACTION TIME; SPECIES DIFFERENCE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; AGED; ANIMALS; BUPROPION; CELL LINE; CORTISONE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSOMES, LIVER; OXIDATION-REDUCTION; PREDNISONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84882764500     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052936     Document Type: Article

References (52)

1. An G, Liu W, Katz DA, Marek G, Awni W, and Dutta S (2013) Effect of ketoconazole on the pharmacokinetics of the 11b-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos 41: 1035-1045.
2. Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, and Mikhailidis DP (2013) 11b-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 62:21-33.
3. Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RA, Frey FJ, Langer T, and Odermatt A (2005) Comparative enzymology of 11b-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 35:89-101.
4. Atanasov AG and Odermatt A (2007) Readjusting the glucocorticoid balance: an opportunity for modulators of 11b-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets 7:125-140.
5. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, and Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28:235-242.
6. Czock D, Keller F, Rasche FM, and Häussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61-98.
7. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
8. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, and Johnston JA (2005) 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7:106-113.
9. Frick C, Atanasov AG, Arnold P, Ozols J, and Odermatt A (2004) Appropriate function of 11b-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-Terminal region sharing similar topological determinants with 50-kDa esterase. J Biol Chem 279:31131-31138.
10. Gathercole LL, Lavery GG, Morgan SA, Cooper MS, Sinclair AJ, Tomlinson JW, and Stewart PM (2013) 11b-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocr Rev DOI: 10.1210/er.2012-1050 [published ahead of print].
11. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, and Potter WZ (1988) Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
12. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, and Mundt SS,, et al. (2005) 11b-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527.
13. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
14. Holm KJ and Spencer CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007-1024.
15. Horst WD and Preskorn SH (1998) Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237-254.
16. Hsyu P-H, Singh A, Giargiari TD, Dunn JA, Ascher JA, and Johnston JA (1997) Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737-743.
17. Hughes KA, Webster SP, and Walker BR (2008) 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 17: 481-496.
18. Hult M, Elleby B, Shafqat N, Svensson S, Rane A, Jörnvall H, Abrahmsen L, and Oppermann U (2004) Human and rodent type 1 11beta- hydroxysteroid dehydrogenases are 7betahydroxycholesterol dehydrogenases involved in oxysterol metabolism. Cell Mol Life Sci 61: 992-999.
19. Hult M, Jörnvall H, and Oppermann UC (1998) Selective inhibition of human type 1 11b-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett 441: 25-28.
20. Hult M, Nobel CS, Abrahmsen L, Nicoll-Griffith DA, Jörnvall H, and Oppermann UC (2001) Novel enzymological profiles of human 11b-hydroxysteroid dehydrogenase type 1. Chem Biol Interact 130-132:805-814.
21. Jafarinia M, Mohammadi M-R, Modabbernia A, Ashrafi M, Khajavi D, Tabrizi M, Yadegari N, and Akhondzadeh S (2012) Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol 27:411-418.
22. Jefferson JW, Pradko JF, and Muir KT (2005) Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 27:1685-1695.
23. Jones G, Willett P, Glen RC, Leach AR, and Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748.
24. Kavanagh KL, Jörnvall H, Persson B, and Oppermann U (2008) Medium-And short-chain dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes. Cell Mol Life Sci 65: 3895-3906.
25. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, and Lai AA (1985) Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 38:586-589.
26. Lavery GG, Zielinska AE, Gathercole LL, Hughes B, Semjonous N, Guest P, Saqib K, Sherlock M, Reynolds G, and Morgan SA,, et al. (2012) Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11b-hydroxysteroid dehydrogenase type 1. Endocrinology 153:3236-3248.
27. Luo MJ, Thieringer R, Springer MS, Wright SD, Hermanowski-Vosatka A, Plump A, Balkovec JM, Cheng K, Ding GJ, and Kawka DW,, et al. (2013) 11b-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature. Physiol Genomics 45:47-57.
28. Martin P, Massol J, Colin JN, Lacomblez L, and Puech AJ (1990) Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23:187-194.
29. Maser E and Bannenberg G (1994) 11 b-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. Biochem Pharmacol 47:1805-1812.
30. Maser E, Friebertshäuser J, and Völker B (2003) Purification, characterization and NNK carbonyl reductase activities of 11b-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem Biol Interact 143-144:435-448.
31. Masuzaki H and Flier JS (2003) Tissue-specific glucocorticoid reactivating enzyme, 11 b-hydroxysteroid dehydrogenase type 1 (11 b-HSD1)-A promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 3:255-262.
32. Meyer A, Vuorinen A, Zielinska AE, Da Cunha T, Strajhar P, Lavery GG, Schuster D, and Odermatt A (2013) Carbonyl reduction of triadimefon by human and rodent 11b-hydroxysteroid dehydrogenase 1. Biochem Pharmacol 85:1370-1378.
33. Molnari JC and Myers AL (2012) Carbonyl reduction of bupropion in human liver. Xenobiotica 42:550-561.
34. Nashev LG, Chandsawangbhuwana C, Balazs Z, Atanasov AG, Dick B, Frey FJ, Baker ME, and Odermatt A (2007) Hexose-6-phosphate dehydrogenase modulates 11b-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto-And 7b-hydroxy-neurosteroids. PLoS ONE 2:e561.
35. Odermatt A, Da Cunha T, Penno CA, Chandsawangbhuwana C, Reichert C, Wolf A, Dong M, and Baker ME (2011) Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11b-hydroxysteroid dehydrogenase 1. Biochem J 436:621-629.
36. Odermatt A and Kratschmar DV (2012) Tissue-specific modulation of mineralocorticoid receptor function by 11b-hydroxysteroid dehydrogenases: an overview. Mol Cell Endocrinol 350: 168-186.
37. Odermatt A and Nashev LG (2010) The glucocorticoid-Activating enzyme 11b-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol 119:1-13.
38. Oppermann UC, Filling C, Berndt KD, Persson B, Benach J, Ladenstein R, and Jörnvall H (1997) Active site directed mutagenesis of 3 b/17 b-hydroxysteroid dehydrogenase establishes differential effects on short-chain dehydrogenase/reductase reactions. Biochemistry 36:34-40.
39. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, and Laine K (2003) Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 74:326-333.
40. Piacentini MF, Meeusen R, Buyse L, De Schutter G, and De Meirleir K (2004) Hormonal responses during prolonged exercise are influenced by a selective DA/NA reuptake inhibitor. Br J Sports Med 38:129-133.
41. Rao U, Ott GE, Lin KM, Gertsik L, and Poland RE (2005) Effect of bupropion on nocturnal urinary free cortisol and its association with antidepressant response. J Psychiatr Res 39:183-190.
42. Rebuffat AG, Tam S, Nawrocki AR, Baker ME, Frey BM, Frey FJ, and Odermatt A (2004) The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Mol Cell Endocrinol 214:27-37.
43. Schroeder DH (1983) Metabolism and kinetics of bupropion. J Clin Psychiatry 44:79-81.
44. Schweizer RA, Zürcher M, Balazs Z, Dick B, and Odermatt A (2004) Rapid hepatic metabolism of 7-ketocholesterol by 11b-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme. J Biol Chem 279:18415-18424.
45. Tiganescu A, Tahrani AA, Morgan SA, Otranto M, Desmoulière A, Abrahams L, Hassan-Smith Z, Walker EA, Rabbitt EH, and Cooper MS,, et al. (2013) 11b-hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest 10.1172/ JCI64162.
46. Venier O, Pascal C, Braun A, Namane C, Mougenot P, Crespin O, Pacquet F, Mougenot C, Monseau C, and Onofri B, et al. (2013) Discovery of SAR184841, a potent and long-lasting inhibitor of 11b-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D. Bioorg Med Chem Lett 23:2414-2421.
47. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, and Taylor RD (2003) Improved proteinligand docking using GOLD. Proteins 52:609-623.
48. Wang X, Abdelrahman DR, Fokina VM, Hankins GD, Ahmed MS, and Nanovskaya TN (2011) Metabolism of bupropion by baboon hepatic and placental microsomes. Biochem Pharmacol 82:295-303.
49. Wang X, Abdelrahman DR, Zharikova OL, Patrikeeva SL, Hankins GDV, Ahmed MS, and Nanovskaya TN (2010) Bupropion metabolism by human placenta. Biochem Pharmacol 79:1684-1690.
50. Welch RM, Lai AA, and Schroeder DH (1987) Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 17:287-298.
51. White PC, Mune T, and Agarwal AK (1997) 11 b-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18:135-156.
52. Wsól V, Szotáková B, Skálová L, and Maser E (2003) Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11b-hydroxysteroid dehydrogenase type 1. Chem Biol Interact 143-144:459-468.